Bluejay Diagnostics, Inc. (BJDX) Details SYMON-II Dataset for IL-6 Sepsis Risk

Bluejay Diagnostics (BJDX) reported preliminary SYMON-II data from 777 patients, showing ~18% 28-day mortality, to evaluate its Symphony IL-6 test for sepsis. The test is not FDA-cleared, and analyses are ongoing.

Original reporting
Published Oct 6, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bluejay Diagnostics, Inc. (BJDX) Details SYMON-II Dataset for IL-6 Sepsis Risk — source image
Decision brief

The 30-second read

$BJDXBullishMed
01

Why it matters

The release provides the first public glimpse of SYMON‑II performance, a key step toward regulatory approval.

02

Market read

Early clinical data could influence BJDX valuation as investors assess clearance prospects.

03

What to watch

The sample size is modest and mortality rate alone may not translate to commercial success.

Relevance 8/10Novelty 8/10Timing: today

Background

Bluejay Diagnostics is a micro‑cap company developing an IL‑6 based test for sepsis risk assessment.

Company-level read

Ticker impact

$BJDXBullishMedium confidence
Context

Bluejay Diagnostics released preliminary SYMON-II baseline data from 777 patients, showing ~18% 28‑day mortality.

Expected impact

potential modest upside as investors price in progress toward clearance

Evidence & confidence

Positive early clinical data can lift sentiment, but the test is not yet cleared and the market may await further results.

Market effects

May boost interest in sepsis diagnostics and related biotech firms.

Limited to US biotech sector.

Low, confined to niche diagnostic market.

Counterpoint

Data are preliminary; without FDA clearance the test may face regulatory hurdles.

Key entities

  • Bluejay Diagnostics, Inc.

    Developer of the Symphony IL‑6 sepsis test.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.